Repurposing old drugs to fight multidrug resistant cancers
- Publication type:
- Journal article
- Metadata:
-
- Autoren
- Jelena Dinic
- Thomas Efferth
- Alfonso T Garcia-Sosa
- Jelena Grahovac
- Jose M Padron
- Ilza Pajeva
- Flavio Rizzolio
- Simona Saponara
- Gabriella Spengler
- Ivanka Tsakovska
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000577090400002&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1016/j.drup.2020.100713
- eISSN
- 1532-2084
- Externe Identifier
- Clarivate Analytics Document Solution ID: NZ4UD
- PubMed Identifier: 32615525
- ISSN
- 1368-7646
- Zeitschrift
- DRUG RESISTANCE UPDATES
- Schlüsselwörter
- Drug repurposing
- Multidrug resistant cancer
- Clinical cancer trials
- Pharmacophore modelling
- Virtual screening
- Artikelnummer
- ARTN 100713
- Datum der Veröffentlichung
- 2020
- Status
- Published
- Titel
- Repurposing old drugs to fight multidrug resistant cancers
- Sub types
- Review
- Ausgabe der Zeitschrift
- 52
Data source: Web of Science (Lite)
- Other metadata sources:
-
- Autoren
- Jelena Dinić
- Thomas Efferth
- Alfonso T García-Sosa
- Jelena Grahovac
- José M Padrón
- Ilza Pajeva
- Flavio Rizzolio
- Simona Saponara
- Gabriella Spengler
- Ivanka Tsakovska
- DOI
- 10.1016/j.drup.2020.100713
- ISSN
- 1368-7646
- Zeitschrift
- Drug Resistance Updates
- Sprache
- en
- Artikelnummer
- 100713
- Paginierung
- 100713 - 100713
- Datum der Veröffentlichung
- 2020
- Status
- Published
- Herausgeber
- Elsevier BV
- Herausgeber URL
- http://dx.doi.org/10.1016/j.drup.2020.100713
- Datum der Datenerfassung
- 2022
- Titel
- Repurposing old drugs to fight multidrug resistant cancers
- Ausgabe der Zeitschrift
- 52
Data source: Crossref
- Abstract
- Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approaches are needed. Herein, we show some practical examples of in silico approaches such as pharmacophore modelling, as well as pharmacophore- and docking-based virtual screening for a fast and cost-effective repurposing of small molecule drugs against multidrug resistant cancers. We provide a timely and comprehensive overview of compounds with considerable potential to be repositioned for cancer therapeutics. These drugs are from diverse chemotherapeutic classes. We emphasize the scope and limitations of anthelmintics, antibiotics, antifungals, antivirals, antimalarials, antihypertensives, psychopharmaceuticals and antidiabetics that have shown extensive immunomodulatory, antiproliferative, pro-apoptotic, and antimetastatic potential. These drugs, either used alone or in combination with existing anticancer chemotherapeutics, represent strong candidates to prevent or overcome drug resistance. We particularly focus on outcomes and future perspectives of drug repositioning for the treatment of multidrug resistant tumors and discuss current possibilities and limitations of preclinical and clinical investigations.
- Addresses
- Department of Neurobiology, Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade, Bulevar Despota Stefana 142, 11060 Belgrade, Serbia.
- Autoren
- Jelena Dinić
- Thomas Efferth
- Alfonso T García-Sosa
- Jelena Grahovac
- José M Padrón
- Ilza Pajeva
- Flavio Rizzolio
- Simona Saponara
- Gabriella Spengler
- Ivanka Tsakovska
- DOI
- 10.1016/j.drup.2020.100713
- eISSN
- 1532-2084
- Externe Identifier
- PubMed Identifier: 32615525
- Open access
- false
- ISSN
- 1368-7646
- Zeitschrift
- Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
- Schlüsselwörter
- Humans
- Neoplasms
- Antineoplastic Agents
- Computational Biology
- Drug Resistance, Multiple
- Drug Resistance, Neoplasm
- Computer Simulation
- Drug Discovery
- Drug Repositioning
- Sprache
- eng
- Medium
- Print-Electronic
- Online publication date
- 2020
- Paginierung
- 100713
- Datum der Veröffentlichung
- 2020
- Status
- Published
- Datum der Datenerfassung
- 2020
- Titel
- Repurposing old drugs to fight multidrug resistant cancers.
- Sub types
- Research Support, Non-U.S. Gov't
- Review
- Journal Article
- Ausgabe der Zeitschrift
- 52
Data source: Europe PubMed Central
- Abstract
- Overcoming multidrug resistance represents a major challenge for cancer treatment. In the search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a tremendous interest during the past years. Repositioning candidates have often emerged through several stages of clinical drug development, and may even be marketed, thus attracting the attention and interest of pharmaceutical companies as well as regulatory agencies. Typically, drug repositioning has been serendipitous, using undesired side effects of small molecule drugs to exploit new disease indications. As bioinformatics gain increasing popularity as an integral component of drug discovery, more rational approaches are needed. Herein, we show some practical examples of in silico approaches such as pharmacophore modelling, as well as pharmacophore- and docking-based virtual screening for a fast and cost-effective repurposing of small molecule drugs against multidrug resistant cancers. We provide a timely and comprehensive overview of compounds with considerable potential to be repositioned for cancer therapeutics. These drugs are from diverse chemotherapeutic classes. We emphasize the scope and limitations of anthelmintics, antibiotics, antifungals, antivirals, antimalarials, antihypertensives, psychopharmaceuticals and antidiabetics that have shown extensive immunomodulatory, antiproliferative, pro-apoptotic, and antimetastatic potential. These drugs, either used alone or in combination with existing anticancer chemotherapeutics, represent strong candidates to prevent or overcome drug resistance. We particularly focus on outcomes and future perspectives of drug repositioning for the treatment of multidrug resistant tumors and discuss current possibilities and limitations of preclinical and clinical investigations.
- Date of acceptance
- 2020
- Autoren
- Jelena Dinić
- Thomas Efferth
- Alfonso T García-Sosa
- Jelena Grahovac
- José M Padrón
- Ilza Pajeva
- Flavio Rizzolio
- Simona Saponara
- Gabriella Spengler
- Ivanka Tsakovska
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/32615525
- DOI
- 10.1016/j.drup.2020.100713
- eISSN
- 1532-2084
- Zeitschrift
- Drug Resist Updat
- Schlüsselwörter
- Clinical cancer trials
- Drug repurposing
- Multidrug resistant cancer
- Pharmacophore modelling
- Virtual screening
- Antineoplastic Agents
- Computational Biology
- Computer Simulation
- Drug Discovery
- Drug Repositioning
- Drug Resistance, Multiple
- Drug Resistance, Neoplasm
- Humans
- Neoplasms
- Sprache
- eng
- Country
- Scotland
- Paginierung
- 100713
- PII
- S1368-7646(20)30042-X
- Datum der Veröffentlichung
- 2020
- Status
- Published
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2021
- Titel
- Repurposing old drugs to fight multidrug resistant cancers.
- Sub types
- Journal Article
- Research Support, Non-U.S. Gov't
- Review
- Ausgabe der Zeitschrift
- 52
Data source: PubMed
- Beziehungen:
- Property of